Intellia Therapeutics, Inc. financial data

Symbol
NTLA on Nasdaq
Location
40 Erie Street, Suite 130, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 565 % -34.4%
Debt-to-equity 27.6 % +25.6%
Return On Equity -57.7 % -16.1%
Return On Assets -45.2 % -10.9%
Operating Margin -969 % +15%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 107M shares +5.68%
Common Stock, Shares, Outstanding 105M shares +7.16%
Entity Public Float 1.92B USD -46.2%
Common Stock, Value, Issued 10K USD 0%
Weighted Average Number of Shares Outstanding, Basic 104M shares +6.97%
Weighted Average Number of Shares Outstanding, Diluted 104M shares +6.97%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 52.9M USD +15%
Research and Development Expense 446M USD -0.67%
General and Administrative Expense 119M USD -1.75%
Costs and Expenses 565M USD -0.9%
Operating Income (Loss) -512M USD +2.3%
Net Income (Loss) Attributable to Parent -480M USD +5.62%
Earnings Per Share, Basic -4 USD/shares +14.6%
Earnings Per Share, Diluted -4 USD/shares +14.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 156M USD +19.4%
Marketable Securities, Current 303M USD -45.8%
Accounts Receivable, after Allowance for Credit Loss, Current 11.4M USD -7.92%
Assets, Current 496M USD -34.5%
Property, Plant and Equipment, Net 22.8M USD -24.7%
Operating Lease, Right-of-Use Asset 129M USD +22.4%
Assets 899M USD -24.6%
Accounts Payable, Current 9.8M USD -47.9%
Employee-related Liabilities, Current 12.4M USD -16.8%
Accrued Liabilities, Current 41.6M USD -7.92%
Contract with Customer, Liability, Current 17.2M USD -22.7%
Liabilities, Current 95.5M USD -9.13%
Contract with Customer, Liability, Noncurrent 12.5M USD -55.3%
Operating Lease, Liability, Noncurrent 75.6M USD -13.4%
Liabilities 184M USD -16.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 653K USD
Retained Earnings (Accumulated Deficit) -2.39B USD -25.1%
Stockholders' Equity Attributable to Parent 715M USD -26.3%
Liabilities and Equity 899M USD -24.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -149M USD -23.4%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 94.3M USD +1499%
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 105M shares +7.16%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -54.6M USD +0.31%
Deferred Tax Assets, Valuation Allowance 783M USD +27.1%
Deferred Tax Assets, Gross 845M USD +30.2%
Operating Lease, Liability 103M USD
Payments to Acquire Property, Plant, and Equipment 735K USD -70.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -478M USD +5.87%
Lessee, Operating Lease, Liability, to be Paid 124M USD
Property, Plant and Equipment, Gross 77.1M USD +6.13%
Operating Lease, Liability, Current 27M USD +42.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 24.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 32.2M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21.5M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 15.6M USD
Deferred Tax Assets, Operating Loss Carryforwards 297M USD +14.7%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 12.7M USD
Depreciation, Depletion and Amortization 2.5M USD -3.85%
Deferred Tax Assets, Net of Valuation Allowance 61.3M USD +89.2%
Share-based Payment Arrangement, Expense 123M USD -15.3%